In a world where longevity is a rare feat, Takeda Pharmaceutical Company Limited stands out as a beacon of endurance and responsibility. With a remarkable 245-year history, this Japanese biopharmaceutical giant has not only survived but thrived, guided by a patient-centric philosophy that has withstood the test of time.
A Legacy of Patient-Centric Care
Takeda's story began in 1781 in Osaka, Japan, and since then, it has grown into a global force, yet its core mission remains unwavering. Dr. Simon Gallagher, the General Manager of Takeda Malaysia and Singapore, emphasizes that their purpose is to serve patients, a commitment that has remained constant throughout their rich history.
What makes Takeda's approach unique is its focus on being more than just a pharmaceutical supplier. In Malaysia, where the company has been present for 22 years, it positions itself as a long-term healthcare partner, dedicated to strengthening the entire ecosystem of diagnosis, treatment, and prevention.
Takeda-ism: A Culture of Values
At the heart of Takeda's culture is a set of core values known as Takeda-ism, encompassing integrity, fairness, honesty, and perseverance. These values are not just words on paper; they are a living framework that guides every decision. The PTRB model (Patient, Trust, Reputation, Business) ensures that patient needs come first, followed by building trust, reinforcing reputation, and then focusing on sustainable business practices.
This philosophy is not just a marketing strategy; it's a deep-rooted belief system that has shaped Takeda's global success. As Gallagher puts it, "Every decision begins with the patient."
Addressing Complex Healthcare Challenges
In Malaysia, Takeda tackles some of the most challenging therapeutic areas, including gastroenterology, oncology, haematology, rare diseases, and vaccines. These areas often involve chronic, complex, and critical diseases that require long-term management and scientific expertise.
One of Takeda's notable contributions is its work on dengue, a persistent public health threat in tropical regions. Through partnerships and advocacy, Takeda supports dengue prevention efforts, aligning with the Malaysian government's goal of zero dengue deaths by 2030.
Strengthening Healthcare Ecosystems
Beyond developing medicines, Takeda recognizes the importance of strengthening the broader healthcare ecosystem. This involves improving diagnosis and disease management across various therapeutic areas. For instance, in gastroenterology, Takeda supported the development of a national consensus on the diagnosis and treatment of Helicobacter pylori, standardizing clinical practices in Malaysia.
In haematology and rare diseases, the company collaborates with healthcare stakeholders to enhance diagnostic pathways, ensuring better care for patients with conditions like haemophilia.
Innovation: A Scientific Journey
Takeda's innovation strategy is patient-centric, focusing on identifying and addressing unmet medical needs. The research and development process involves rigorous clinical trials to demonstrate safety, efficacy, and quality.
What sets Takeda apart is its commitment to continuing the scientific journey even after a product's launch. By collecting real-world evidence, they ensure that their therapies deliver meaningful outcomes for patients across diverse populations.
Partnerships: Building Future-Ready Healthcare
Partnerships are key to Takeda's vision of a future-ready healthcare system. By collaborating with policymakers, healthcare professionals, advocacy groups, and industry stakeholders, Takeda aims to co-create solutions that strengthen patient care.
This involves value-based partnerships, medical education programs, and knowledge sharing to ensure that innovative treatments are understood and effectively integrated into clinical practice.
Looking Ahead: A Patient-First Future
As Takeda continues to expand its global research pipeline, its presence in Malaysia is expected to grow. Over the next five years, the company plans to launch up to nine new products, targeting conditions like sleep disorders and attention deficit hyperactivity disorder.
While new products are exciting, Gallagher emphasizes that Takeda's ultimate goal remains unchanged: ensuring patients have access to the right medicine at the right time. This patient-first philosophy, which has guided Takeda for nearly two and a half centuries, is a testament to the company's enduring competitive advantage in a complex and ever-evolving healthcare landscape.
